Targeting RTK Signaling Pathways in Cancer

被引:292
作者
Regad, Tarik [1 ]
机构
[1] Nottingham Trent Univ, John Van Geest Canc Res Ctr, Sch Sci & Technol, Clifton Lane, Nottingham NG11 8NS, England
关键词
RTK; MAP kinase; PI3K; AKT; small molecule inhibitors; cancer; GROWTH-FACTOR-RECEPTOR; SQUAMOUS-CELL CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMORS; METASTATIC BREAST-CANCER; TYROSINE KINASE DOMAIN; AFATINIB BIBW 2992; C-MET; LUNG-CANCER; PROTEIN-KINASE;
D O I
10.3390/cancers7030860
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The RAS/MAP kinase and the RAS/PI3K/AKT pathways play a key role in the regulation of proliferation, differentiation and survival. The induction of these pathways depends on Receptor Tyrosine Kinases (RTKs) that are activated upon ligand binding. In cancer, constitutive and aberrant activations of components of those pathways result in increased proliferation, survival and metastasis. For instance, mutations affecting RTKs, Ras, B-Raf, PI3K and AKT are common in perpetuating the malignancy of several types of cancers and from different tissue origins. Therefore, these signaling pathways became prime targets for cancer therapy. This review aims to provide an overview about the most frequently encountered mutations, the pathogenesis that results from such mutations and the known therapeutic strategies developed to counteract their aberrant functions.
引用
收藏
页码:1758 / 1784
页数:27
相关论文
共 182 条
  • [11] Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer
    Bernard-Pierrot, Isabelle
    Gruel, Nadege
    Stransky, Nicolas
    Vincent-Salomon, Anne
    Reyal, Fabien
    Raynal, Virginie
    Vallot, Celine
    Pierron, Gaelle
    Radvanyi, Francois
    Delattre, Olivier
    [J]. CANCER RESEARCH, 2008, 68 (17) : 7165 - 7175
  • [12] Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
    Beroukhim, Rameen
    Getz, Gad
    Nghiemphu, Leia
    Barretina, Jordi
    Hsueh, Teli
    Linhart, David
    Vivanco, Igor
    Lee, Jeffrey C.
    Huang, Julie H.
    Alexander, Sethu
    Du, Jinyan
    Kau, Tweeny
    Thomas, Roman K.
    Shah, Kinial
    Soto, Horacio
    Perner, Sven
    Prensner, John
    Debiasi, Ralph M.
    Demichelis, Francesca
    Hatton, Charlie
    Rubin, Mark A.
    Garraway, Levi A.
    Nelson, Stan F.
    Liau, Linda
    Mischel, Paul S.
    Cloughesy, Tim F.
    Meyerson, Matthew
    Golub, Todd A.
    Lander, Eric S.
    Mellinghoff, Ingo K.
    Sellers, William R.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (50) : 20007 - 20012
  • [13] Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
    Bhagwat, Shripad V.
    Gokhale, Prafulla C.
    Crew, Andrew P.
    Cooke, Andy
    Yao, Yan
    Mantis, Christine
    Kahler, Jennifer
    Workman, Jennifer
    Bittner, Mark
    Dudkin, Lorina
    Epstein, David M.
    Gibson, Neil W.
    Wild, Robert
    Arnold, Lee D.
    Houghton, Peter J.
    Pachter, Jonathan A.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (08) : 1394 - 1406
  • [14] Integrin β1 signaling is necessary for transforming growth factor-β activation of p38MAPK and epithelial plasticity
    Bhowmick, NA
    Zent, R
    Ghiassi, M
    McDonnell, M
    Moses, HL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (50) : 46707 - 46713
  • [15] Mitogen-activated protein (MAP) Kinase/MAP kinase phosphatase regulation: Roles in cell growth, death, and cancer
    Boutros, Tarek
    Chevet, Eric
    Metrakos, Peter
    [J]. PHARMACOLOGICAL REVIEWS, 2008, 60 (03) : 261 - 310
  • [16] A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
    Bowles, D. W.
    Ma, W. W.
    Senzer, N.
    Brahmer, J. R.
    Adjei, A. A.
    Davies, M.
    Lazar, A. J.
    Vo, A.
    Peterson, S.
    Walker, L.
    Hausman, D.
    Rudin, C. M.
    Jimeno, A.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 109 (05) : 1085 - 1092
  • [17] Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
    Brose, Marcia S.
    Nutting, Christopher M.
    Jarzab, Barbara
    Elisei, Rossella
    Siena, Salvatore
    Bastholt, Lars
    de la Fouchardiere, Christelle
    Pacini, Furio
    Paschke, Ralf
    Shong, Young Kee
    Sherman, Steven I.
    Smit, Johannes W. A.
    Chung, John
    Kappeler, Christian
    Pena, Carol
    Molnar, Istvan
    Schlumberger, Martin J.
    [J]. LANCET, 2014, 384 (9940) : 319 - 328
  • [18] SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
    Buchanan, Sean G.
    Hendle, Jorg
    Lee, Patrick S.
    Smith, Christopher R.
    Bounaud, Pierre-Yves
    Jessen, Katti A.
    Tang, Crystal M.
    Huser, Nanni H.
    Felce, Jeremy D.
    Froning, Karen J.
    Peterman, Marshall C.
    Aubol, Brandon E.
    Gessert, Steve F.
    Sauder, Michael
    Schwinn, Kenneth D.
    Russell, Marijane
    Rooney, Isabelle A.
    Adams, Jason
    Leon, Barbara C.
    Do, Tuan H.
    Blaney, Jeff M.
    Sprengeler, Paul A.
    Thompson, Devon A.
    Smyth, Lydia
    Pelletier, Laura A.
    Atwell, Shane
    Holme, Kevin
    Wasserman, Stephen R.
    Emtage, Spencer
    Burley, Stephen K.
    Reich, Siegfried H.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12) : 3181 - 3190
  • [19] Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
    Campbell, Robert M.
    Anderson, Bryan D.
    Brooks, Nathan A.
    Brooks, Harold B.
    Chan, Edward M.
    De Dios, Alfonso
    Gilmour, Raymond
    Graff, Jeremy R.
    Jambrina, Enrique
    Mader, Mary
    McCann, Denis
    Na, Songqing
    Parsons, Stephen H.
    Pratt, Susan E.
    Shih, Chuan
    Stancato, Louis F.
    Starling, James J.
    Tate, Courtney
    Velasco, Juan A.
    Wang, Yong
    Ye, Xiang S.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2014, 13 (02) : 364 - 374
  • [20] Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
    Cappellen, D
    De Oliveira, C
    Ricol, D
    de Medina, SGD
    Bourdin, J
    Sastre-Garau, X
    Chopin, D
    Thiery, JP
    Radvanyi, F
    [J]. NATURE GENETICS, 1999, 23 (01) : 18 - 20